FDA Clears First Single-Biomarker Blood Test for Alzheimer’s Disease

FDA Clears First Single-Biomarker Blood Test for Alzheimer’s Disease

The US Food and Drug Administration (FDA) has cleared the Elecsys Phospho-Tau (217P) Plasma test — better known as the pTau217 blood test — making it the first single-biomarker blood test cleared to help evaluate Alzheimer’s disease in adults aged 55 and older who are experiencing signs, symptoms or complaints of cognitive decline. The announcement, made by Roche Diagnostics on 24 August 2026, marks a significant step towards simpler, more accessible Alzheimer’s testing in both primary and specialty care settings.

What is the pTau217 blood test?

The Elecsys pTau217 test measures a single protein biomarker in the blood: phosphorylated tau at threonine 217 (pTau217). Elevated levels of this protein are closely linked to the accumulation of amyloid plaques in the brain — one of the hallmark changes of Alzheimer’s disease.

Unlike earlier Alzheimer’s blood tests that combine multiple measurements — such as a pTau217-to-amyloid-beta ratio — this test interprets pTau217 on its own. According to the manufacturer, a low result indicates amyloid pathology is unlikely, while a high result suggests it is much more likely.

Why this clearance matters

Historically, confirming the biology behind a person’s cognitive decline has been difficult. Definitive testing for amyloid plaques usually required either:

• a positron emission tomography (PET) brain scan, which is expensive and only available at specialised centres, or
• a lumbar puncture (spinal tap) to sample cerebrospinal fluid, which is invasive and uncomfortable for patients

As a result, many people faced long periods of uncertainty, and some were diagnosed only after their disease had progressed. Blood-based biomarkers offer a faster, less invasive and potentially more affordable path to answers.

“Currently, many patients face prolonged uncertainty because traditional dementia diagnostics like brain scans and spinal taps are prohibitively expensive, physically invasive, and restricted to specialized medical centers,” said Dr Manisha Parulekar, division chief of geriatrics at Hackensack Meridian Health in the US. “Blood biomarkers offer a transformative alternative.”

Who is the test for?

The test is cleared for adults aged 55 years and older who already have signs, symptoms or complaints of cognitive decline. It is designed to be used alongside clinical evaluation, not as a standalone diagnosis.

Experts stress that the pTau217 blood test is not a screening test for healthy people. Alzheimer’s biology can begin years before symptoms appear, and a positive biomarker result in a cognitively normal person cannot yet predict whether — or when — they will develop symptoms.

“If someone is cognitively normal and the biomarker comes back positive, we cannot yet tell them with certainty whether they will develop symptoms — or when,” said Dr Davide Cappon, director of neuropsychology at Tufts Medical Center. “This test is intended for people who already have cognitive symptoms or concerns.”

What the test can and cannot tell you

Key points for patients and clinicians to understand:

• The test helps rule in or rule out amyloid pathology — it does not diagnose Alzheimer’s on its own.
• Results must be interpreted together with a doctor’s clinical assessment of memory, thinking and daily function.
• A positive result does not mean dementia is inevitable, and a negative result does not exclude all causes of cognitive decline.
• The test runs on widely available laboratory analysers, which means hospitals and clinics may be able to offer it using existing equipment.

Some neurologists have also urged caution about broader use. Dr Clifford Segil, a neurologist at Providence Saint John’s Health Center in California, noted that clinicians ordering the test need to be confident interpreting positive and negative results — and that primary care doctors may require additional support and guidance in counselling patients about what the results mean.

What does this mean for the future of dementia care?

The clearance reflects a broader shift in dementia diagnosis. Just over a year ago, no FDA-cleared blood tests existed for Alzheimer’s disease. Today, several are available, and the Elecsys pTau217 is the first to rely on a single biomarker — potentially making testing simpler, more consistent and easier to scale across different laboratory settings.

Earlier and more accurate identification of amyloid pathology could also help more people access emerging Alzheimer’s treatments and participate in clinical trials, while giving families earlier answers and a clearer direction for care planning.

Roche has not yet publicly announced pricing or the commercial rollout timeline. Availability outside the United States, including in Australia, will depend on local regulatory approvals — the test is not yet universally available worldwide.

Frequently Asked Questions

Q: What is the pTau217 blood test?
A: The pTau217 blood test (Elecsys Phospho-Tau (217P) Plasma) measures a single protein biomarker, phosphorylated tau at threonine 217, to help identify whether amyloid plaques — a hallmark of Alzheimer’s disease — are likely present in the brain.

Q: Who should have the pTau217 test?
A: The test is cleared for adults aged 55 and older who have signs, symptoms or complaints of cognitive decline. It is not recommended as a screening test for people without memory concerns.

Q: Does a positive pTau217 result mean I have Alzheimer’s disease?
A: Not on its own. A positive result indicates amyloid pathology is likely, but a diagnosis of Alzheimer’s requires a clinician to combine the test result with a full assessment of symptoms, medical history and other findings.

Q: How is this test different from previous Alzheimer’s blood tests?
A: Earlier cleared tests combined multiple biomarkers, such as a pTau217-to-amyloid-beta ratio, and some required specialised laboratory handling. The Elecsys pTau217 test measures a single biomarker and is designed to run on widely available laboratory analysers, including in primary care settings.

Q: Is the pTau217 blood test available in Australia?
A: Not yet. The test has been cleared by the US FDA, but availability in Australia will depend on registration with the Therapeutic Goods Administration (TGA) and local commercial decisions by the manufacturer. People with memory concerns should speak to their doctor about the most appropriate assessment options currently available.

Q: Will a blood test replace memory clinics and specialist assessment?
A: No. Blood biomarkers are expected to complement — not replace — specialist assessment. They may help streamline referrals, reduce the need for more invasive testing, and speed up access to appropriate care and support.

The bottom line

The FDA clearance of the Elecsys pTau217 test is a meaningful milestone in the move towards earlier, less invasive and more accessible evaluation of Alzheimer’s disease. For health professionals, it underscores the growing role of blood biomarkers in dementia care — and the importance of interpreting them within a thorough clinical framework. Anyone concerned about memory changes should seek medical advice rather than requesting biomarker testing independently.